MetLife Investment Management LLC Has $7.65 Million Stake in Insmed, Inc. $INSM

Key Points

• MetLife Investment Management LLC reduced its stake in Insmed, Inc. by 3.1%, owning approximately 100,210 shares valued at $7.65 million.
• Insmed, Inc. reported a quarterly revenue of $107.42 million, missing the EPS estimate but showing an 18.9% year-over-year increase.
• Analysts have a consensus rating of "Moderate Buy" for Insmed, with price targets raised by multiple firms, currently averaging $132.57.

MetLife Investment Management LLC trimmed its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 100,210 shares of the biopharmaceutical company's stock after selling 3,219 shares during the period. MetLife Investment Management LLC owned approximately 0.06% of Insmed worth $7,645,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Cullen Frost Bankers Inc. lifted its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP acquired a new position in Insmed in the fourth quarter valued at approximately $28,000. NBC Securities Inc. acquired a new position in Insmed in the first quarter valued at approximately $49,000. Versant Capital Management Inc lifted its holdings in Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares during the period. Finally, Signaturefd LLC lifted its holdings in Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 325 shares during the period.

Insmed Stock Up 1.8%

Shares of NASDAQ:INSM opened at $134.53 on Thursday. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $134.74. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market capitalization of $28.44 billion, a PE ratio of -23.56 and a beta of 0.95. The company has a 50 day moving average price of $109.35 and a two-hundred day moving average price of $86.71.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period in the previous year, the company posted ($1.94) EPS. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 25,000 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the completion of the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO William Lewis sold 6,865 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $128.40, for a total transaction of $881,466.00. Following the sale, the chief executive officer directly owned 233,924 shares of the company's stock, valued at $30,035,841.60. This represents a 2.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 539,694 shares of company stock valued at $53,144,604 over the last three months. Insiders own 3.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. UBS Group increased their price objective on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a report on Friday, August 8th. Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Jefferies Financial Group increased their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Finally, Royal Bank Of Canada increased their price objective on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $132.57.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.